Relapsed Cancer Clinical Trial
— GBrecurrOfficial title:
Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.
NCT number | NCT06430424 |
Other study ID # | CHUBX 2023/79 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 2024 |
Est. completion date | April 2026 |
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | April 2026 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - age > 18 years - surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux Exclusion Criteria: - systemic therapy received for non-glioblastoma tumor |
Country | Name | City | State |
---|---|---|---|
France | CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of metabolic changes involved in glioblastoma relapse | Relative abondance of metabolite and differential enzyme expression in a recurrence versus primary sample | Up to 2 years after the start of the study | |
Secondary | Progression-free survival | Progression-free survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse measured at time of inclusion | From date of the second surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
Secondary | Overall survival | Overall survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse | From date of the second surgery until the date of death from any cause, assessed up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03336931 -
PRecISion Medicine for Children With Cancer
|
||
Recruiting |
NCT05852717 -
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
|
Phase 2 | |
Terminated |
NCT04092179 -
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT06024603 -
Individualized Treatments in Adults With Relapsed/Refractory Cancers
|
N/A | |
Active, not recruiting |
NCT03187288 -
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
|
Phase 1 | |
Recruiting |
NCT04292119 -
Lorlatinib Combinations in Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04310345 -
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
|
N/A | |
Recruiting |
NCT05274451 -
A Study to Investigate LYL797 in Adults With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05662397 -
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05922501 -
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
Completed |
NCT04275102 -
Three Times Weekly Symptom Screening for Children With Cancer
|
N/A | |
Recruiting |
NCT06004167 -
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
|
N/A | |
Recruiting |
NCT05631574 -
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
|
Phase 1 | |
Completed |
NCT03765099 -
Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents
|
N/A | |
Active, not recruiting |
NCT03445858 -
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
|
Early Phase 1 | |
Terminated |
NCT05641324 -
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
|
Phase 1 | |
Recruiting |
NCT04510636 -
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT05504772 -
Precision Medicine for Every Child With Cancer
|
||
Recruiting |
NCT05693831 -
myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
|
||
Recruiting |
NCT04421560 -
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
|
Phase 1/Phase 2 |